Study on antitumor molecular mechanism of Chelidonium majus based on network pharmacology / 中草药

ABSTRACT

Objective Chelidonium majus is applied to tumor therapy with good clinical effect and weak adverse effect. To explain the molecular mechanism of antitumor effect scientifically, the network pharmacology method was used to screen effective parts and major active components of C. majus and to construct the active compounds-targets network. Methods ADME calculation method was used to filtrate the active components of C. majus, and then the targets of the main active ingredients were collected by literature mining and multiple databases, and the targets of the compound were screened using the SysDT model. Besides, the compounds-targets network was constructed by Cytoscape software and network topology analysis was carried out. Biological information annotation databases (DAVID) was used to analyze the molecular function and biological pathway of the action targets. Results Alkaloids were the major active components of C. majus, 21 alkaloid components were screened out by ADME calculation method with 168 related targets, and 60 closely cancer-related pathways. Those pathways were integrated, with which a comprehensive C. majus antitumor pathway was constructed. According to the results of network topology analysis and ingredient correction results, it was speculated that chelerythrine, berberine and sanguinarine were the main active ingredients in C. majus, acting on the targets of PTGS2, SCN5A, F10, NCOA2, CHRM3, AR, TP5, CASP1/3/9, DRD1, MAPT, MAPK1, BLM, etc. Conclusion The antitumor activities of C. majus were mainly by inducing cell apoptosis and inhibiting cell proliferation, metastasis and invasion as phenotype intervention mode in network, thereby to exert antitumor activities and a certain central analgesic effect.